AJP - Heart and Circulatory Physiology, Vol 260, Issue 3 909-H916, Copyright © 1991 by American Physiological Society

ARTICLES

Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats

J. Tong, P. K. Ganguly and P. K. Singal
Division of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, Winnipeg, Canada.

Changes in myocardial norepinephrine (NE) levels, turnover, uptake, and release in rats were examined at two stages of cardiac dysfunction induced by adriamycin (ADR) given intraperitoneally in six equal doses over a period of 2 wk for a cumulative dose of 15 mg/kg. At 3 wk posttreatment, ADR-treated animals showed no changes in left ventricular systolic pressure (LVSP), aortic systolic pressure (ASP), and aortic diastolic pressure (ADP) but left ventricular end-diastolic pressure (LVEDP) was significantly higher. At 6 wk posttreatment, LVSP, ASP, and ADP were significantly lower and LVEDP remained elevated. Animals in both ADR-treated groups showed signs of congestive heart failure as indicated by ascites, congestive liver, and elevated LVEDP. Structural changes typical of ADR cardiomyopathy were more pronounced in the 6-wk group. In vivo hemodynamic as well as in vitro muscle function response to different concentrations of epinephrine was depressed in its duration as well as extent in both 3- and 6-wk ADR-treated groups. Myocardial NE levels were increased in the 3-wk group but were depressed in the 6-wk group. NE turnover was faster in both 3- and 6-wk ADR groups, uptake was increased only in the 6-wk group, and release was unchanged. These data show increased cardiac sympathetic tone at both stages of ADR-induced congestive heart failure.

This article has been cited by other articles:

				A. J. Chicco, D. S. Hydock, C. M. Schneider, and R. Hayward Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity J Appl Physiol, February 1, 2006; 100(2): 519 - 527. [Abstract] [Full Text] [PDF]

				E. Rabelo, K. De Angelis, P. Bock, T. Gatelli Fernandes, F. Cervo, A. Bello Klein, N. Clausell, and M. Claudia Irigoyen Baroreflex Sensitivity and Oxidative Stress in Adriamycin-Induced Heart Failure Hypertension, September 1, 2001; 38(3): 576 - 580. [Abstract] [Full Text] [PDF]

				T. Li and P. K. Singal Adriamycin-Induced Early Changes in Myocardial Antioxidant Enzymes and Their Modulation by Probucol Circulation, October 24, 2000; 102(17): 2105 - 2110. [Abstract] [Full Text] [PDF]

				T. Ueyama, T. Ohkusa, Y. Hisamatsu, Y. Nakamura, T. Yamamoto, M. Yano, and M. Matsuzaki Alterations in cardiac SR Ca2+-release channels during development of heart failure in cardiomyopathic hamsters Am J Physiol Heart Circ Physiol, January 1, 1998; 274(1): H1 - H7. [Abstract] [Full Text] [PDF]

				N. Siveski-Iliskovic, M. Hill, D.A. Chow, and P.K. Singal Probucol Protects Against Adriamycin Cardiomyopathy Without Interfering With Its Antitumor Effect Circulation, January 1, 1995; 91(1): 10 - 15. [Abstract] [Full Text]